Leonard Saltz, MD, executive director for Clinical Value & Sustainability, head, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center, discusses the option of FOLFIRINOX for the treatment of patients with metastatic colorectal cancer.
Leonard Saltz, MD
Advertisement
Articles by Leonard Saltz, MD
Leonard Saltz, MD, Executive Director for Clinical Value & Sustainability, head, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center, discusses chemotherapy for patients with metastatic colorectal cancer.
Advertisement
Latest Updated Articles
Dr. Saltz Discusses Chemotherapy in Metastatic CRCPublished: December 12th 2017 | Updated:
Dr. Saltz Discusses FOLFIRINOX in Colorectal CancerPublished: January 17th 2018 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
4
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
5